-+ 0.00%
-+ 0.00%
-+ 0.00%

Ocular Therapeutix Announced That Enrollment In The SOL-R Registrational Trial Of Its Product Candidate Axpaxli In Wet Age-related Macular Degeneration Will Close This Week, Top-Line Readout Expected In 1Q 2026

Benzinga·05/28/2025 11:05:24
Listen to the news
  • Enrollment for SOL-R, the largest retinal TKI trial to date, supports randomization of at least 555 subjects
  • SOL-1, Ocular's first registrational trial in wet AMD, completed randomization in December 2024 and retention remains exceptional as the trial continues on track for top-line readout in 1Q 2026
  • These two complementary trials are intended to form the basis of an NDA submission of AXPAXLI in wet AMD